• 1
    Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 42633.
  • 2
    Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37: 103541.
  • 3
    Roach M III, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 96574.
  • 4
    Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl. Compr. Canc. Netw. 2010; 8: 162200.
  • 5
    Ciezki JP, Reddy CA, Stephenson AJ et al. The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment. Urology 2010; 75: 46771.
  • 6
    Kirilova A, Damyanovich A, Crook J, Jezioranski J, Wallace K, Pintilie M. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA “bounce” following 125iodine brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011; 79: 3718.
  • 7
    McGrath SD, Antonucci JV, Fitch DL et al. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy 2010; 9: 13744.
  • 8
    Ko EC, Stone NN, Stock RG. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int. J. Radiat. Oncol. Biol. Phys. 2012; 83: 6007.
  • 9
    Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 3140.
  • 10
    Hayden A, Morris WJ, Keyes M et al. The PSA value at 4–5 years after permanent prostate brachytherapy predicts for biochemical failure free survival. Radiother. Oncol. 2010; 96 (Suppl 2): S1S68.
  • 11
    Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. 2000; 163: 10859.
  • 12
    Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J. Urol. 1996; 155: 197780.
  • 13
    Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin. Urol. Oncol. 2000; 18: 1605.
  • 14
    Ciezki JP, Reddy CA, Garcia J et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 51217.
  • 15
    Morita M, Lederer JL, Fukagai T, Shimada M, Yoshida H. PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer. Nihon Hinyokika Gakkai Zasshi 2004; 95: 60915.
  • 16
    Das P, Chen MH, Valentine K et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 698702.
  • 17
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 4506.
  • 18
    Critz FA, Williams WH, Levinson AK et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J. Urol. 2003; 170: 18647.
  • 19
    Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56: 44853.
  • 20
    Patel C, Elshaikh MA, Angermeier K et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004; 63: 11013.
  • 21
    Toledano A, Chauveinc L, Flam T et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Brachytherapy 2006; 5: 1226.
  • 22
    Pickles T, British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 13559.
  • 23
    Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP. Analysis of prostate-specific antigen bounce after I125 permanent seed implant for localised prostate cancer. Radiother. Oncol. 2008; 88: 1027.
  • 24
    Satoh T, Ishiyama H, Matsumoto K et al. Prostate-specific antigen “bounce” after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int. 2009; 103: 10648.
  • 25
    Thompson A, Keyes M, Pickles T et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces? Int. J. Radiat. Oncol. Biol. Phys. 2010; 78: 41521.
  • 26
    Caloglu M, Ciezki JP, Reddy CA et al. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int. J. Radiat. Oncol. Biol. Phys. 2011; 80: 73541.
  • 27
    Hinnen KA, Monninkhof EM, Battermann JJ, van Roermund JG, Frank SJ, van Vulpen M. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2012; 82: 8828.
  • 28
    Bachand F, Martin AG, Beaulieu L, Harel F, Vigneault E. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int. J. Radiat. Oncol. Biol. Phys. 2009; 73: 67984.
  • 29
    Rosser CJ, Kamat AM, Wang X et al. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 2005; 66: 32731.
  • 30
    Gomez-Iturriaga Pina A, Crook J, Borg J, Lockwood G, Fleshner N. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged < or = 55 years with favorable prostate cancer. Urology 2010; 75: 141216.
  • 31
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 35567.
  • 32
    Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1993; 27: 317.
  • 33
    Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J. Urol. 2011; 185: 495500.
  • 34
    Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J. Urol. 2007; 177: 175963; duscussion 1763–4.
  • 35
    Reed D, Wallner K, Merrick G, Buskirk S, True L. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003; 62: 6838.
  • 36
    Crook J, Patil N, Ma C, McLean M, Borg J. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77: 107984.